钙调素抑制剂在肾移植中的应用进展  

Progress on Application of Calcineurin Inhibitors in Renal Transplantation

作　　者：张跃辉[1] 凌建煜[1] 

机构地区：[1]上海第二医科大学仁济医院肾移植中心,上海200127

出　　处：《上海第二医科大学学报》2005年第5期528-531,共4页Acta Universitatis Medicinalis Secondae Shanghai

摘　　要：环孢素A(CsA)作为一种强效免疫抑制剂应用于肾移植以后,明显改善了器官移植短期和中期的疗效。由于CsA在应用中的个体化差异和毒副作用,导致了长期疗效不甚理想。随着更为有效、安全的新型免疫抑制药物的不断推出和临床应用,使钙调素抑制剂(CNIs)的减量和停用方案已成为可能。本文就CNIs在肾移植术后引起的相关肾毒性病理改变及减量或停用方案作一综述。Cyclosporin has become the most important immunosuppressive agent employed in renal transplantation, and its use has led to dramatic improvement in the short- and medium-term outcomes for solid organ transplantation. However, its long-term outcome has been less impressive, partly due to the side effects, and partly to the individual difference of cyclosporin. With introduction of new immunosuppressive drugs it is possible to further reduce the dose of calcineurin inhibitors (CNIs), and propose cyclosporin-free immunosuppressive regimens. This review analyzes the histopathologic findings of CNIs-related nephrotoxicity and presents clinical studies which justify this therapeutic approach.

关 键 词：钙调素抑制剂 肾移植 免疫抑制药物 制剂应用 器官移植 毒副作用 长期疗效 临床应用 病理改变 环孢素 个体化 CSA 肾毒性 术后引 减量 

分 类 号：R699[医药卫生—泌尿科学]